ALX40-4C antiviral: Began a Phase I/II trial in 40 patients to assess anti-CMV effect by viral load and measures of immune status. Groups of eight patients will

Allelix Biopharmaceuticals Inc. (TSE:AXB), Toronto Product: ALX40-4C antiviral Indication: Cytomegalovirus (CMV) in AIDS Status: Began a Phase I/II trial in 40 patients to assess anti-CMV effect by vi...